Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04596995 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT04596995 is a Phase 3 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 43 participants.
The verdict
NCT04596995, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.
Interventions
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04596995
The ClinicalTrials.gov registry entry for NCT04596995 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rozanolixizumab is the first listed.
NCT04596995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04596995 about?
NCT04596995 is a clinical study titled "A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)". The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.
What is the current status of trial NCT04596995?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2021-01-06. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT04596995?
The interventions under investigation include: Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT04596995?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.